When Is Antipsychotic Polypharmacy Supported by Research Evidence? Implications for QI-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

When Is Antipsychotic Polypharmacy Supported by Research Evidence? Implications for QI

Published:2008-10 Issue:10 Volume:34 Page:571-582
ISSN:1553-7250
Container-title:The Joint Commission Journal on Quality and Patient Safety
language:en
Short-container-title:The Joint Commission Journal on Quality and Patient Safety

Author:

Gören Jessica L.,Parks Joseph J.,Ghinassi Frank A.,Milton Celeste G.,Oldham John M.,Hernandez Pablo,Chan Jeffrey,Hermann Richard C.

Publisher

Elsevier BV

Subject

Leadership and Management

Reference83 articles.

1. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia;Lieberman;N Eng J Med,2005

2. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company, 2007.

3. Risperdal [package insert]. Titusville, NJ: Janssen LP, 2007.

4. Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2008.

5. Abilify [package insert]. Princeton, NJ: Bristol Myers Squibb, 2007.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Readmission Rates of Patients Discharged on Antipsychotic Polypharmacy Compared to Antipsychotic Monotherapy;Community Mental Health Journal;2022-10-15

2. Polypharmacy in children and adolescents initiating antipsychotic drug in 2008–2016: a nationwide register study;Nordic Journal of Psychiatry;2022-03-09

3. Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?;Expert Opinion on Pharmacotherapy;2020-11-30

4. Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups?;Asian Journal of Psychiatry;2020-08

5. Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders;Journal of Affective Disorders;2019-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3